OPA115360
HRH4 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | OPA115360-Each-of-1 | In Stock | ₹ 49,083.50 |
OPA115360 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 49,083.50
GST (18%): ₹ 8,835.03
Total Price: ₹ 57,918.53
Antigen
HRH4
Classification
Polyclonal
Conjugate
Unconjugated
Gene
HRH4
Gene Alias
AXOR35; BG26; GPCR105; Gprc105; G-protein coupled receptor 105; GPRv53; H4; H4R; HH4R; histamine H4 receptor; histamine receptor; histamine receptor H4; Hrh4; MGC130500; Pfi-013; SP9144
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
59340
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunohistochemistry (Paraffin)
Concentration
1 mg/mL
Formulation
PBS with 0.1% sodium azide
Gene Accession No.
Q9H3N8
Gene Symbols
HRH4
Immunogen
Synthetic peptide (KLH conjugated) to the 1st cytoplasmic loop.
Quantity
25 μg
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- By immunohistochemistry, OPA1-15360 detects the Histamine H4 receptor in formalin fixed, paraffin embedded human tissues
- The Histamine H4 receptor has been reported in human blood peripheral leukocytes, bone marrow, colon, liver, lung, smalll intestine, spleen, testis, thymus, tonsil, and trachea
- Contrary to the mouse H4 receptor, the human gene was not detected in brain
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more thana thousandmembers currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This "eturn-off"e activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Twoblockbuster drugs which have been developed as GPCR-targetedpharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.